Outlook Therapeutics, Inc. OTLK
We take great care to ensure that the data presented and summarized in this overview for Outlook Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in OTLK
Top Purchases
Top Sells
About OTLK
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Insider Transactions at OTLK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 26
2024
|
Lawrence A Kenyon Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+45.68%
|
$25,000
$5.69 P/Share
|
|
Apr 15
2024
|
Syntone Ventures LLC |
BUY
Open market or private purchase
|
Direct |
714,286
+29.52%
|
-
|
|
Mar 28
2024
|
Yezan Munther Haddadin |
BUY
Open market or private purchase
|
Direct |
1,881
+27.15%
|
$20,691
$11.82 P/Share
|
|
Mar 18
2024
|
Ghiath M. Sukhtian Director |
BUY
Grant, award, or other acquisition
|
Indirect |
2,305,714
+28.42%
|
-
|
|
Mar 07
2024
|
Jeff Evanson CHIEF COMMERCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
62,484
+7.17%
|
$0
$0.42 P/Share
|
|
Apr 20
2023
|
Terry Dagnon Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
520,000
-44.33%
|
$520,000
$1.14 P/Share
|
|
Jan 20
2023
|
Jeff Evanson CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
267,000
-26.36%
|
$267,000
$1.11 P/Share
|
|
Jan 19
2023
|
Jeff Evanson CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
103,255
-9.25%
|
$103,255
$1.22 P/Share
|
|
Jan 18
2023
|
Jeff Evanson CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
33,738
-2.93%
|
$33,738
$1.25 P/Share
|
|
Jan 17
2023
|
Jeff Evanson CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
27,162
-2.31%
|
$27,162
$1.31 P/Share
|
|
Dec 28
2022
|
Ghiath M. Sukhtian Director |
BUY
Grant, award, or other acquisition
|
Indirect |
14,230,418
+16.89%
|
$0
$0.88 P/Share
|
|
Oct 07
2022
|
Faisal Ghiath Sukhtian |
BUY
Open market or private purchase
|
Direct |
30,000
+30.61%
|
$30,000
$1.29 P/Share
|
|
Oct 07
2022
|
Yezan Munther Haddadin |
BUY
Open market or private purchase
|
Direct |
3,600
+5.38%
|
$3,600
$1.27 P/Share
|
|
Oct 06
2022
|
Yezan Munther Haddadin |
BUY
Open market or private purchase
|
Direct |
29,743
+33.24%
|
$29,743
$1.29 P/Share
|
|
Oct 05
2022
|
Kurt J Hilzinger |
BUY
Open market or private purchase
|
Direct |
15,662
+3.2%
|
$15,662
$1.23 P/Share
|
|
Oct 04
2022
|
Kurt J Hilzinger |
BUY
Open market or private purchase
|
Direct |
95,541
+17.28%
|
$95,541
$1.29 P/Share
|
|
Oct 03
2022
|
Kurt J Hilzinger |
BUY
Open market or private purchase
|
Direct |
41,798
+10.35%
|
$41,798
$1.25 P/Share
|
|
Sep 30
2022
|
Kurt J Hilzinger |
BUY
Open market or private purchase
|
Direct |
33,199
+9.4%
|
$33,199
$1.26 P/Share
|
|
Sep 29
2022
|
Kurt J Hilzinger |
BUY
Open market or private purchase
|
Direct |
13,800
+4.59%
|
$13,800
$1.19 P/Share
|
|
Jun 21
2022
|
C Russell Trenary Iii CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
19,925
+26.62%
|
$19,925
$1.06 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 784K shares |
|---|---|
| Grant, award, or other acquisition | 2.31M shares |